Renal Risk Reduction in T2D

CE / CME

Navigating the Latest Evidence and Strategies for Renal Risk Reduction in T2D

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: December 23, 2024

Expiration: December 22, 2025

David Charytan
David Charytan, MD, MSc
Jennifer B Green
Jennifer B Green, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, David Charytan, MD, MSc, and Jennifer B. Green, MD, discuss the most recent evidence and innovative strategies for reducing renal risk in patients with type 2 diabetes (T2D). Both experts highlight key strategies to optimize care, improve patient outcomes, and address challenges in managing renal complications in patients with T2D, with an emphasis on personalized, evidence-based approaches to enhance kidney protection.   

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions are asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with type 2 diabetes and renal disease do you provide care for in a typical week?

GLP-1 RAs are thought to reduce the risk of CKD through which of the following mechanisms?

In an individual with T2D and CKD already taking a RAAS inhibitor and an SGLT2 inhibitor, which of the following would be most appropriate to recommend to further reduce their risk of renal disease progression?

A patient with T2D, high-risk ASCVD, and CKD is managed on metformin and dapagliflozin. Their A1C remains elevated at 8.5%. Which of the following medications should be recommended to optimize their treatment?

Up to now, how likely were you to recommend GLP-1 RAs for kidney risk reduction in patients with T2D?